Compare Quest Diagnostics Inc (DGX) vs Star Bulk Carriers Corp (SBLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Star Bulk Carriers Corp — how do they compare? Quest Diagnostics Inc trades at $205.37 (market cap $22.80B), while Star Bulk Carriers Corp trades at $26.46 (market cap $2.96B). The key difference: Quest Diagnostics Inc is far larger — about 7.7× Star Bulk Carriers Corp's market cap, and Star Bulk Carriers Corp pays the higher dividend (3.88%). Which is the better fit depends on your goals.
| DGX | SBLK | |
|---|---|---|
Market Cap | $22.80B | $2.96B |
Sector | Health | Industrials |
52-Week High | $216.02 | $28.21 |
52-Week Low | $166.42 | $16.79 |
Enterprise Value | $28.82B | $3.66B |
Dividend Yield | 1.67% | 3.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Star Bulk Carriers (SBLK) trades at $26.54, up 0.72% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with Q1 2026 earnings beating expectations at $0.56 EPS versus $0.475 expected, while maintaining a healthy 13.01% net income margin. Recent news highlights robust dry bulk rates supporting potential double-digit dividend yields, with the company's modernizing fleet and opportunistic asset sales strengthening the balance sheet.
SBLK presents a compelling opportunity with strong cash flow generation and shareholder returns, though investors face risks from spot rate volatility and cyclical shipping demand. Wall Street maintains bullish sentiment with 14 buy ratings versus 2 sells, while technical indicators show potential resistance near $27 levels. The company's disciplined capital allocation and fleet renewal strategy provide upside potential if dry bulk markets remain favorable.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Star Bulk Carriers Corp
Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →
